{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T22:10:42Z","timestamp":1781302242876,"version":"3.54.1"},"reference-count":52,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2016,6,1]],"date-time":"2016-06-01T00:00:00Z","timestamp":1464739200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,6,1]],"date-time":"2016-06-01T00:00:00Z","timestamp":1464739200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,16]],"date-time":"2023-08-16T00:00:00Z","timestamp":1692144000000},"content-version":"vor","delay-in-days":2632,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","award":["R01 AG048650-01A1"],"award-info":[{"award-number":["R01 AG048650-01A1"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"name":"NIH","award":["P30 MH62512"],"award-info":[{"award-number":["P30 MH62512"]}]}],"content-domain":{"domain":["neurotherapeuticsjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurotherapeutics"],"published-print":{"date-parts":[[2016,6]]},"DOI":"10.1007\/s13311-016-0454-2","type":"journal-article","created":{"date-parts":[[2016,7,6]],"date-time":"2016-07-06T09:59:01Z","timestamp":1467799141000},"page":"471-476","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Update and New Directions in Therapeutics for Neurological Complications of HIV Infections"],"prefix":"10.1016","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4931-752X","authenticated-orcid":false,"given":"Ronald","family":"Ellis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott L.","family":"Letendre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1007\/s13311-016-0454-2_bib1","doi-asserted-by":"crossref","unstructured":"Ances, B. M. and D. B. Clifford (2008). HIV-associated neurocognitive disorders and the impact of combination antiretroviral therapies. Curr Neurol Neurosci Rep 8(6): 455-461.","DOI":"10.1007\/s11910-008-0073-3"},{"key":"10.1007\/s13311-016-0454-2_bib2","doi-asserted-by":"crossref","unstructured":"Andrade, R. M., F. J. Torriani and R. J. Ellis (2014). Acute HIV infection presenting as fulminant meningoencephalitis with massive CSF viral replication. Neurology: Clinical Practice 4(3): 256-259.","DOI":"10.1212\/CPJ.0000000000000037"},{"key":"10.1007\/s13311-016-0454-2_bib3","doi-asserted-by":"crossref","unstructured":"Antonelli, L. R., Y. Mahnke, J. N. Hodge, et al. (2010). Elevated frequencies of highly activated CD4+ T cells in HIV+ patients developing immune reconstitution inflammatory syndrome. Blood 116(19): 3818-3827.","DOI":"10.1182\/blood-2010-05-285080"},{"key":"10.1007\/s13311-016-0454-2_bib4","doi-asserted-by":"crossref","unstructured":"Aquaro, S., R. Calio, J. Balzarini, M. C. Bellocchi, E. Garaci and C. F. Perno (2002). Macrophages and HIV infection: therapeutical approaches toward this strategic virus reservoir. Antiviral Res 55(2): 209-225.","DOI":"10.1016\/S0166-3542(02)00052-9"},{"key":"10.1007\/s13311-016-0454-2_bib5","doi-asserted-by":"crossref","unstructured":"Baker, L. D., S. M. Barsness, S. Borson, et al. (2012). Effects of growth hormone-releasing hormone on cognitive function in adults with mild cognitive impairment and healthy older adults: results of a controlled trial. Arch Neurol 69(11): 1420-1429.","DOI":"10.1001\/archneurol.2012.1970"},{"key":"10.1007\/s13311-016-0454-2_bib6","doi-asserted-by":"crossref","unstructured":"Boelaert, J. R., K. H. Goddeeris, L. J. Vanopdenbosch and J. W. Casselman (2004). Relapsing meningitis caused by persistent cryptococcal antigens and immune reconstitution after the initiation of highly active antiretroviral therapy. Aids 18(8): 1223-1224.","DOI":"10.1097\/00002030-200405210-00023"},{"key":"10.1007\/s13311-016-0454-2_bib7","doi-asserted-by":"crossref","unstructured":"Boulware, D. R., D. B. Meya, C. Muzoora, et al. (2014). Timing of antiretroviral therapy after diagnosis of cryptococcal meningitis. N Engl J Med 370(26): 2487-2498.","DOI":"10.1056\/NEJMoa1312884"},{"key":"10.1007\/s13311-016-0454-2_bib8","doi-asserted-by":"crossref","unstructured":"Canestri, A., F. X. Lescure, S. Jaureguiberry, et al. (2010). Discordance between cerebral spinal fluid and plasma HIV replication in patients with neurological symptoms who are receiving suppressive antiretroviral therapy. Clin Infect Dis 50(5): 773-778.","DOI":"10.1086\/650538"},{"key":"10.1007\/s13311-016-0454-2_bib9","doi-asserted-by":"crossref","unstructured":"Chun, T. W. (1997). Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. Proc Natl Acad Sci U S A 94: 13193-13197.","DOI":"10.1073\/pnas.94.24.13193"},{"key":"10.1007\/s13311-016-0454-2_bib10","doi-asserted-by":"crossref","unstructured":"Chun, T. W., L. Carruth, D. Finzi, et al. (1997). Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection. Nature 387(6629): 183-188.","DOI":"10.1038\/387183a0"},{"key":"10.1007\/s13311-016-0454-2_bib11","doi-asserted-by":"crossref","unstructured":"Clifford, D. B. and B. M. Ances (2013). HIV-associated neurocognitive disorder. Lancet Infect Dis 13(11): 976-986.","DOI":"10.1016\/S1473-3099(13)70269-X"},{"key":"10.1007\/s13311-016-0454-2_bib12","doi-asserted-by":"crossref","unstructured":"Craft, S. and G. S. Watson (2004). Insulin and neurodegenerative disease: shared and specific mechanisms. Lancet Neurol 3(3): 169-178.","DOI":"10.1016\/S1474-4422(04)00681-7"},{"key":"10.1007\/s13311-016-0454-2_bib13","doi-asserted-by":"crossref","unstructured":"Crump, J. A., M. J. Tyrer, S. J. Lloyd-Owen, L. Y. Han, M. C. Lipman and M. A. Johnson (1998). Military tuberculosis with paradoxical expansion of intracranial tuberculomas complicating human immunodeficiency virus infection in a patient receiving highly active antiretroviral therapy. Clin Infect Dis 26(4): 1008-1009.","DOI":"10.1086\/517636"},{"key":"10.1007\/s13311-016-0454-2_bib14","doi-asserted-by":"crossref","unstructured":"Cysique, L. A., F. Vaida, S. Letendre, et al. (2009). Dynamics of cognitive change in impaired HIV-positive patients initiating antiretroviral therapy. Neurology 73(5): 342-348.","DOI":"10.1212\/WNL.0b013e3181ab2b3b"},{"key":"10.1007\/s13311-016-0454-2_bib15","doi-asserted-by":"crossref","unstructured":"Cysique, L. A., E. K. Waters and B. J. Brew (2011). Central nervous system antiretroviral efficacy in HIV infection: a qualitative and quantitative review and implications for future research. BMC Neurol 11: 148.","DOI":"10.1186\/1471-2377-11-148"},{"key":"10.1007\/s13311-016-0454-2_bib16","doi-asserted-by":"crossref","unstructured":"Deeks, S. G., R. Tracy and D. C. Douek (2013). Systemic effects of inflammation on health during chronic HIV infection. Immunity 39(4): 633-645.","DOI":"10.1016\/j.immuni.2013.10.001"},{"key":"10.1007\/s13311-016-0454-2_bib17","doi-asserted-by":"crossref","unstructured":"Eden, A., D. Fuchs, L. Hagberg, et al. (2010). \u201cHIV-1 viral escape in cerebrospinal fluid of subjects on suppressive antiretroviral treatment.\u201d J Infect Dis 202(12): 1819-1825.","DOI":"10.1086\/657342"},{"key":"10.1007\/s13311-016-0454-2_bib18","unstructured":"Ellis, R. (2016). Tesamorelin for Cognition in HIV. Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02572323?term=Ellis+tesamorelin&rank=1."},{"key":"10.1007\/s13311-016-0454-2_bib19","doi-asserted-by":"crossref","unstructured":"Ellis, R. J., S. Letendre, F. Vaida, et al. (2014). Randomized trial of central nervous system-targeted antiretrovirals for HIV-associated neurocognitive disorder. Clin Infect Dis 58(7): 1015-1022.","DOI":"10.1093\/cid\/cit921"},{"key":"10.1007\/s13311-016-0454-2_bib20","doi-asserted-by":"crossref","unstructured":"Feinstein, R., H. Kanety, M. Z. Papa, B. Lunenfeld and A. Karasik (1993). Tumor necrosis factor-alpha suppresses insulin-induced tyrosine phosphorylation of insulin receptor and its substrates. J Biol Chem 268(35): 26055-26058.","DOI":"10.1016\/S0021-9258(19)74276-8"},{"key":"10.1007\/s13311-016-0454-2_bib21","doi-asserted-by":"crossref","unstructured":"Foley, J., Ettenhofer, M., Wright M. J., et al. (2010). CH Neurocognitive functioning in HIV-1 infection: effects of cerebrovascular risk factors and age. Clin Neuropsychol 24(2):265\u2013285. 10.1080\/13854040903482830","DOI":"10.1080\/13854040903482830"},{"key":"10.1007\/s13311-016-0454-2_bib22","doi-asserted-by":"crossref","unstructured":"French, M. A. (2009). HIV\/AIDS: immune reconstitution inflammatory syndrome: a reappraisal. Clin Infect Dis 48(1): 101-107.","DOI":"10.1086\/595006"},{"key":"10.1007\/s13311-016-0454-2_bib23","doi-asserted-by":"crossref","unstructured":"French, M. A., M. S. King, J. M. Tschampa, B. A. da Silva and A. L. Landay (2009). Serum immune activation markers are persistently increased in patients with HIV infection after 6 years of antiretroviral therapy despite suppression of viral replication and reconstitution of CD4+ T cells. J Infect Dis 200(8): 1212-1215.","DOI":"10.1086\/605890"},{"key":"10.1007\/s13311-016-0454-2_bib24","doi-asserted-by":"crossref","unstructured":"Grabmeier-Pfistershammer, K., P. Steinberger, A. Rieger, J. Leitner and N. Kohrgruber (2011). Identification of PD-1 as a unique marker for failing immune reconstitution in HIV-1-infected patients on treatment. J Acquir Immune Defic Syndr 56(2): 118-124.","DOI":"10.1097\/QAI.0b013e3181fbab9f"},{"key":"10.1007\/s13311-016-0454-2_bib25","doi-asserted-by":"crossref","unstructured":"Heaton, R. K., D. B. Clifford, D. R. Franklin, Jr., et al. (2010). HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER Study. Neurology 75(23): 2087-2096.","DOI":"10.1212\/WNL.0b013e318200d727"},{"key":"10.1007\/s13311-016-0454-2_bib26","doi-asserted-by":"crossref","unstructured":"Ho, Y. C., L. Shan, N. N. Hosmane, et al. (2013). Replication-competent noninduced proviruses in the latent reservoir increase barrier to HIV-1 cure. Cell 155(3): 540-551.","DOI":"10.1016\/j.cell.2013.09.020"},{"key":"10.1007\/s13311-016-0454-2_bib27","doi-asserted-by":"crossref","unstructured":"Hocqueloux, L., V. Avettand-Fenoel, S. Jacquot, et al. (2013). Long-term antiretroviral therapy initiated during primary HIV-1 infection is key to achieving both low HIV reservoirs and normal T cell counts. J Antimicrob Chemother 68(5): 1169-1178.","DOI":"10.1093\/jac\/dks533"},{"key":"10.1007\/s13311-016-0454-2_bib28","doi-asserted-by":"crossref","unstructured":"Hoen, B., I. Fournier, C. Lacabaratz, et al. (2005). Structured treatment interruptions in primary HIV-1 infection: the ANRS 100 PRIMSTOP trial. J Acquir Immune Defic Syndr 40(3): 307-316.","DOI":"10.1097\/01.qai.0000182628.66713.31"},{"key":"10.1007\/s13311-016-0454-2_bib29","doi-asserted-by":"crossref","unstructured":"Hunt, P. W., J. N. Martin, E. Sinclair, et al. (2003). T cell activation is associated with lower CD4+ T cell gains in human immunodeficiency virus-infected patients with sustained viral suppression during antiretroviral therapy. J Infect Dis 187(10): 1534-1543.","DOI":"10.1086\/374786"},{"key":"10.1007\/s13311-016-0454-2_bib30","doi-asserted-by":"crossref","unstructured":"Kim, J. A., M. Montagnani, K. K. Koh and M. J. Quon (2006). Reciprocal relationships between insulin resistance and endothelial dysfunction: molecular and pathophysiological mechanisms. Circulation 113(15): 1888-1904.","DOI":"10.1161\/CIRCULATIONAHA.105.563213"},{"key":"10.1007\/s13311-016-0454-2_bib31","doi-asserted-by":"crossref","unstructured":"Kranick, S. M., P. H. Goncalves, M. Stetler-Stevenson, et al. (2015). Paradoxical central nervous system immune reconstitution syndrome in acquired immunodeficiency syndrome-related primary central nervous system lymphoma. Haematologica 100(1): e21-e24.","DOI":"10.3324\/haematol.2014.114736"},{"key":"10.1007\/s13311-016-0454-2_bib32","doi-asserted-by":"crossref","unstructured":"Kranick, S. M. and A. Nath (2012). Neurologic complications of HIV-1 infection and its treatment in the era of antiretroviral therapy. Continuum (Minneap Minn) 18: 1319-1337.","DOI":"10.1212\/00132979-201212000-00005"},{"key":"10.1007\/s13311-016-0454-2_bib33","doi-asserted-by":"crossref","unstructured":"Krishnan, S., J. T. Schouten, B. Atkinson, et al. (2015). Changes in metabolic syndrome status after initiation of antiretroviral therapy. J Acquir Immune Defic Syndr 68(1): 73-80.","DOI":"10.1097\/QAI.0000000000000397"},{"key":"10.1007\/s13311-016-0454-2_bib34","doi-asserted-by":"crossref","unstructured":"Kumar, A. and G. Herbein (2014). The macrophage: a therapeutic target in HIV-1 infection. Mol Cell Ther 2(1): 1-15.","DOI":"10.1186\/2052-8426-2-10"},{"key":"10.1007\/s13311-016-0454-2_bib35","doi-asserted-by":"crossref","unstructured":"Letendre, S. L., J. A. McCutchan, M. E. Childers, et al. (2004). Enhancing antiretroviral therapy for human immunodeficiency virus cognitive disorders. Ann Neurol 56(3): 416-423.","DOI":"10.1002\/ana.20198"},{"key":"10.1007\/s13311-016-0454-2_bib36","doi-asserted-by":"crossref","unstructured":"Li, J. Z., B. Etemad, H. Ahmed, et al. (2016). The size of the expressed HIV reservoir predicts timing of viral rebound after treatment interruption. Aids 30(3): 343-353.","DOI":"10.1097\/01.aids.0000499516.66930.89"},{"key":"10.1007\/s13311-016-0454-2_bib37","doi-asserted-by":"crossref","unstructured":"McComsey, G. A., C. C. Whalen, S. D. Mawhorter, et al. (2001). Placebo-controlled trial of prednisone in advanced HIV-1 infection. Aids 15(3): 321-327.","DOI":"10.1097\/00002030-200102160-00004"},{"key":"10.1007\/s13311-016-0454-2_bib38","doi-asserted-by":"crossref","unstructured":"Miravalle, A., R. Jensen and R. P. Kinkel (2011). Immune reconstitution inflammatory syndrome in patients with multiple sclerosis following cessation of natalizumab therapy. Arch Neurol 68(2): 186-191.","DOI":"10.1001\/archneurol.2010.257"},{"key":"10.1007\/s13311-016-0454-2_bib39","doi-asserted-by":"crossref","unstructured":"Palella, F. J., Jr., R. K. Baker, A. C. Moorman, et al. (2006). \u201cMortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV outpatient study.\u201d J Acquir Immune Defic Syndr 43(1): 27-34.","DOI":"10.1097\/01.qai.0000233310.90484.16"},{"key":"10.1007\/s13311-016-0454-2_bib40","doi-asserted-by":"crossref","unstructured":"Pilcher, C. D., D. C. Shugars, S. A. Fiscus, et al. (2001). HIV in body fluids during primary HIV infection: implications for pathogenesis, treatment and public health. Aids 15(7): 837-845.","DOI":"10.1097\/00002030-200105040-00004"},{"key":"10.1007\/s13311-016-0454-2_bib41","doi-asserted-by":"crossref","unstructured":"Post, M. J., M. M. Thurnher, D. B. Clifford, et al. (2013). CNS-immune reconstitution inflammatory syndrome in the setting of HIV infection, part 1: overview and discussion of progressive multifocal leukoencephalopathy-immune reconstitution inflammatory syndrome and cryptococcal-immune reconstitution inflammatory syndrome. AJNR Am J Neuroradiol 34(7): 1297-1307.","DOI":"10.3174\/ajnr.A3183"},{"key":"10.1007\/s13311-016-0454-2_bib42","doi-asserted-by":"crossref","unstructured":"Rajasuriar, R., G. Khoury, A. Kamarulzaman, M. A. French, P. U. Cameron and S. R. Lewin (2013). Persistent immune activation in chronic HIV infection: do any interventions work? AIDS 27(8): 1199-1208.","DOI":"10.1097\/QAD.0b013e32835ecb8b"},{"key":"10.1007\/s13311-016-0454-2_bib43","doi-asserted-by":"crossref","unstructured":"Schouten, J., P. Cinque, M. Gisslen, P. Reiss and P. Portegies (2011). HIV-1 infection and cognitive impairment in the cART era: a review. Aids 25(5): 561-575.","DOI":"10.1097\/QAD.0b013e3283437f9a"},{"key":"10.1007\/s13311-016-0454-2_bib44","doi-asserted-by":"crossref","unstructured":"Shikuma, C. M., B. Nakamoto, B. Shiramizu, et al. (2012). Antiretroviral monocyte efficacy score linked to cognitive impairment in HIV. Antivir Ther 17(7): 1233-1242.","DOI":"10.3851\/IMP2411"},{"key":"10.1007\/s13311-016-0454-2_bib45","doi-asserted-by":"crossref","unstructured":"Soontornniyomkij, V., A. Umlauf, S. A. Chung, et al. (2014). HIV protease inhibitor exposure predicts cerebral small vessel disease. AIDS 28(9): 1297-1306.","DOI":"10.1097\/QAD.0000000000000262"},{"key":"10.1007\/s13311-016-0454-2_bib46","doi-asserted-by":"crossref","unstructured":"Spudich, S. (2013). HIV and neurocognitive dysfunction. Curr HIV\/AIDS Rep 10(3): 235-243.","DOI":"10.1007\/s11904-013-0171-y"},{"key":"10.1007\/s13311-016-0454-2_bib47","doi-asserted-by":"crossref","unstructured":"Thornhill, J., S. Fidler and J. Frater (2015). Advancing the HIV cure agenda: the next 5 years. Curr Opin Infect Dis 28(1): 1-9.","DOI":"10.1097\/QCO.0000000000000123"},{"key":"10.1007\/s13311-016-0454-2_bib48","doi-asserted-by":"crossref","unstructured":"Wong, J. K., M. Hezareh, H. F. Gunthard, et al. (1997). Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science 278(5341): 1291-1295.","DOI":"10.1126\/science.278.5341.1291"},{"key":"10.1007\/s13311-016-0454-2_bib49","doi-asserted-by":"crossref","unstructured":"Worsley, C. M., M. S. Suchard, W. S. Stevens, A. Van Rie and D. M. Murdoch (2010). Multi-analyte profiling of ten cytokines in South African HIV-infected patients with Immune Reconstitution Inflammatory Syndrome (IRIS). AIDS Res Ther 7: 36-36.","DOI":"10.1186\/1742-6405-7-36"},{"key":"10.1007\/s13311-016-0454-2_bib50","unstructured":"Yilmaz, A. and M. Gisslen (2014). Treatment of HIV in the central nervous system. Semin Neurol 34(1): 14-20."},{"key":"10.1007\/s13311-016-0454-2_bib51","doi-asserted-by":"crossref","unstructured":"Zlokovic, B. V. (2008). The blood-brain barrier in health and chronic neurodegenerative disorders. Neuron 57(2): 178-201.","DOI":"10.1016\/j.neuron.2008.01.003"},{"key":"10.1007\/s13311-016-0454-2_bib52","doi-asserted-by":"crossref","unstructured":"Zlokovic, B. V. (2011). Neurovascular pathways to neurodegeneration in Alzheimer's disease and other disorders. Nat Rev Neurosci 12(12): 723-738.","DOI":"10.1038\/nrn3114"}],"container-title":["Neurotherapeutics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13311-016-0454-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s13311-016-0454-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747923009169?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747923009169?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13311-016-0454-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13311-016-0454-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T06:48:02Z","timestamp":1761806882000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1878747923009169"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,6]]},"references-count":52,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2016,6]]}},"alternative-id":["S1878747923009169"],"URL":"https:\/\/doi.org\/10.1007\/s13311-016-0454-2","relation":{},"ISSN":["1878-7479"],"issn-type":[{"value":"1878-7479","type":"print"}],"subject":[],"published":{"date-parts":[[2016,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Update and New Directions in Therapeutics for Neurological Complications of HIV Infections","name":"articletitle","label":"Article Title"},{"value":"Neurotherapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1007\/s13311-016-0454-2","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2016 The American Society for Experimental NeuroTherapeutics, Inc. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}